X.T.L. Biopharmaceuticals
Open
$3.43
Prev. Close
$3.40
High
$3.43
Low
$3.43
Market Snapshot
-1.10
$451K
33
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
emptyResult
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
Recently from Cashu
Servier Acquires Day One Biopharmaceuticals to Enhance Oncology Portfolio
Strategic Acquisition Enhances Biopharmaceutical Capabilities for Servier In a significant development within the biopharmaceutical industry, Day One Biopharmaceuticals announces its acquisition by Se…
X.T.L. Biopharmaceuticals Partners with LOTTE Biologics to Enhance Cancer Therapy Manufacturing
Rakuten Medical Enhances Manufacturing Capabilities through Strategic Partnership with LOTTE Biologics In a significant development at the J.P. Morgan Healthcare Conference, Rakuten Medical, Inc. anno…
X.T.L. Biopharmaceuticals Makes Significant Strides in mRNA Therapeutics Development and Clinical Trials
X.T.L. Biopharmaceuticals Advances in mRNA Therapeutics Development X.T.L. Biopharmaceuticals, a frontrunner in the mRNA therapeutics space, announces significant progress in its proprietary drug deve…
X.T.L. Biopharmaceuticals Explores Innovative Obesity Treatments at Taiwan Medical Association Congress
Innovative Approaches to Obesity Management: Insights from Caliway Biopharmaceuticals' Research Caliway Biopharmaceuticals recently unveils its promising preclinical research on CBL-514 at the 25th An…